Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

Hepatology

Volumn 62, Issue 1, 2015, Pages 79-86

  Reddy, K Rajender ^a   Bourlière, Marc ^b   Sulkowski, Mark ^c   Omata, Masao ^d   Zeuzem, Stefan ^e   Feld, Jordan J ^f   Lawitz, Eric ^g   Marcellin, Patrick ^h   Welzel, Tania M ^e   Hyland, Robert ⁱ   Ding, Xiao ⁱ   Yang, Jenny ⁱ   Knox, Steven ⁱ   Pang, Phillip ⁱ   Dvory Sobol, Hadas ⁱ   Subramanian, G Mani ⁱ   Symonds, William ⁱ   Mchutchison, John G ⁱ   Mangia, Alessandra ^j   Gane, Edward ^k   Mizokami, Masashi ^l   Pol, Stanislas ^h   Afdhal, Nezam ^m   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HÔPITAL SAINT JOSEPH   (France)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Yamanashi Prefectural Hospital Organization   (Japan)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ GILEAD SCIENCES   (United States)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

^l NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^m BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; COMPENSATED LIVER CIRRHOSIS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; THROMBOCYTE COUNT; TREATMENT DURATION; VOMITING; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84933181270     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27826     Document Type: Article

References (21)

1. Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int 2013;33(Suppl 1):46-55.
2. Gane E. Future perspectives: towards interferon-free regimens for HCV. Antivir Ther 2012;17:1201-1210.
3. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al.; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-142.e4.
4. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59:434-441.
5. Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real-world experience from HCV-TARGET. J Hepatol 2015;62:286-293.
6. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-640.
7. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir and sofosbuvir for 12 weeks with ribavirin or for 24 weeks alone in patients with genotype 1 HCV infection and cirrhosis in whom prior protease inhibitor therapy failed: a randomized, double-blind, phase 2 trial. Lancet Infect Dis 2015;15:397-404.
8. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
9. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
10. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al.; HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597-1605.
11. Harvoni (ledipasvir-sofosbuvir) tablets. U.S. prescribing information. Gilead Sciences: Foster City, California, 2015.
12. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. Available at: http://www.hcvguidelines.org. Accessed January 9, 2015.
13. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
14. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia ES, Pang PS, et al. Once daily sofosbuvir/ledipasvir fixed-dose combination with or without ribavirin: data from the ELECTRON trials. EASL 2013. [AASLD Abstract 73]. Hepatology 2013;58:243A.
15. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-743.e1.
16. Lawitz E, Poordad F, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C: an open-label, randomized, phase 2 trial (LONESTAR). Lancet 2014;383:515-523.
17. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al.; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
18. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al.; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
19. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762-768.
20. Alqahtani S, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo PY, et al. Safety of ledipasvir/sofosbuvir with and without ribavirin for the treatment of patients with chronic HCV genotype 1 infection: an analysis of the phase 3 ION trials. 65th Annual Meeting of the American Association for the Study of Liver Diseases, November 7-11, 2014, Boston, MA.
21. Lawitz E, Rodriguez-Torres M, Cornpropst M, Denning J, Clemons D, McNair L, et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days. 47th Annual Meeting of the European Association for the Study of the Liver, April 18-22, 2012, Barcelona, Spain.